This is a pilot study of single dose of 225Ac-J591 at 90 KBq/Kg in men with progressive metastatic castration resistant prostate cancer (mCRPC).

The study will test an investigational product called VCN-01 in patients with metastatic pancreatic cancer. “Investigational” means that VCN-01 has not been approved by the U.S. Food and Drug Administration (FDA) to treat any disease.

This study is evaluating the drugs nab-paclitaxel and gemcitabine in combination with avutometinib (VS-6766) and defactinib for patients with pancreatic ductal adenocarcinoma.

The purpose of the study is to better understand if, how and to what extent art therapy may help patients receiving treatment for cancer or hematology illnesses. This is an observational study and does not involve any interventions.

Our broad objective is to quantify surgeon performance, build automated assessments grounded in patient-centered outcomes, and develop quality assurance programs to improve training for surgeons.
   

This clinical trial is for adult participants who have an advanced or metastatic solid tumor and have received prior standard therapy.
   

The purpose of this study is to determine the effectiveness of a new ultrasound technique to detect cancer and/or other abnormalities in lymph nodes, small bean-shaped structures that are part of the body's immune system. Participants in this study will have at least one lymph node that may be larger than normal. 

The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on Merkel cell carcinoma.

The purpose of this study is to test the safety and effectiveness of the experimental combination of tazemetostat with chimeric antigen receptor t-cell (CAR T) cell therapy, and see what effects it has on lymphoma. An additional purpose of this study is to understand what side effects people may have when they receive both drugs together.

This clinical trial is for men and women with newly diagnosed Acute Myeloid Lymphoma (AML) who are not eligible for intensive chemotherapy.
   
The purpose of this study is to evaluate the safety and effectiveness of the addition of an experimental drug, magrolimab, in combination with venetoclax and azacitidine compared to venetoclax and azacitidine alone.
   
Experimental means that magrolimab has not yet been approved by the U.S. Food and Drug Administration (FDA).